Perspectives on the development of a molecularly targeted agent

Brian J. Druker

doi:10.1016/S1535-6108(02)00025-9

Perspectives on the development of a molecularly targeted agent

Brian J. Druker

Knight Cancer Institute

Research output: Contribution to journal › Review article › peer-review

244 Scopus citations

Abstract

STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.

Original language	English (US)
Pages (from-to)	31-36
Number of pages	6
Journal	Cancer Cell
Volume	1
Issue number	1
DOIs	https://doi.org/10.1016/S1535-6108(02)00025-9
State	Published - Feb 2002

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/S1535-6108(02)00025-9

Cite this

@article{de7fd9f02edf4624a10500452b1d1e2c,

title = "Perspectives on the development of a molecularly targeted agent",

abstract = "STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.",

author = "Druker, {Brian J.}",

note = "Funding Information: B.J.D. is funded by grants from the NCI, a Specialized Center of Research Award from The Leukemia and Lymphoma Society, a Clinical Scientist Award from the Burroughs Wellcome Fund, and the T. J. Martell Foundation. B.J.D. has served as a consultant to Novartis Pharmaceuticals.",

year = "2002",

month = feb,

doi = "10.1016/S1535-6108(02)00025-9",

language = "English (US)",

volume = "1",

pages = "31--36",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Perspectives on the development of a molecularly targeted agent

AU - Druker, Brian J.

N1 - Funding Information: B.J.D. is funded by grants from the NCI, a Specialized Center of Research Award from The Leukemia and Lymphoma Society, a Clinical Scientist Award from the Burroughs Wellcome Fund, and the T. J. Martell Foundation. B.J.D. has served as a consultant to Novartis Pharmaceuticals.

PY - 2002/2

Y1 - 2002/2

N2 - STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.

AB - STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.

UR - http://www.scopus.com/inward/record.url?scp=0036463948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036463948&partnerID=8YFLogxK

U2 - 10.1016/S1535-6108(02)00025-9

DO - 10.1016/S1535-6108(02)00025-9

M3 - Review article

C2 - 12086885

AN - SCOPUS:0036463948

SN - 1535-6108

VL - 1

SP - 31

EP - 36

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -

Perspectives on the development of a molecularly targeted agent

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this